PCL, Inc. terminated the acquisition of 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd.
December 11, 2022
Share
PCL, Inc. (KOSDAQ:A241820) agreed to acquire 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc (KOSDAQ:A226950), Samyang Holdings Corporation (KOSE:A000070), AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. (KOSDAQ:A027360) and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. for KRW12.2 billion on November 11, 2022. PCL, Inc. will acquire 0.54 million equity shares in mCureX Therapeutics, Inc. mCureX Therapeutics, Inc reported Total assets worth KRW 5.98 billion and net loss of KRW -1.1 billion in year ending December 31, 2021.
PCL, Inc. (KOSDAQ:A241820) terminated the acquisition of 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc (KOSDAQ:A226950), Samyang Holdings Corporation (KOSE:A000070), AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. (KOSDAQ:A027360) and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. on December 12, 2022.
AJU IB INVESTMENT Co., Ltd. is a Korea-based company mainly engaged in the venture capital (VC) business and private equity (PE) business. The Company invests in small to medium enterprises (SMEs) and venture companies, provides initial public offering (IPO), merger and acquisitions (M&A), secondary support services, among others. The Company also operates private equity funds (PEF), provides mezzanine, buyout and corporate restructuring services.
PCL, Inc. terminated the acquisition of 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd.